Stocks Health care FBIOP
NASDAQ · Health careFortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. brought in $68.5M of revenue over the twelve months to June 30, 2026, up 15.5% from a year earlier. Net income was $111.8M, a net margin of 163.3%. At June 30, 2026 it held $196.6M in cash against $35M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Fortress Biotech, Inc. does
Fortress Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBIOP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $63.3M | $6.8M | -$0.07 | n/a |
| 2024 | $57.7M | -$46M | -$2.69 | -$80.2M |
| 2023 | $84.5M | -$60.6M | -$8.47 | -$128.3M |
| 2022 | $75.7M | -$86.6M | -$15.97 | -$182.1M |
| 2021 | $68.8M | -$64.7M | -$13.01 | -$121.1M |
| 2020 | $45.6M | -$46.5M | -$10.70 | -$85.6M |
Latest SEC filings
What Fortress Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- June 23, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Quarterly report 10-Q · period to March 31, 2026
- May 14, 2026
- April 28, 2026Additional proxy material DEFA14A
- April 28, 2026Proxy statement DEF 14A
- March 31, 2026Annual report 10-K · period to December 31, 2025
Questions about FBIOP
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBIOP.
Is Fortress Biotech, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $111.8M on revenue of $68.5M, a net margin of 163.3%.
How much revenue does Fortress Biotech, Inc. make?
Over the twelve months to June 30, 2026 Fortress Biotech, Inc. reported revenue of $68.5M. That is 15.5% more than a year earlier.
When did Fortress Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 1, 2026.
Similar companies
Follow FBIOP
Get an email when Fortress Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow FBIOP: get an email when it filesWhere the numbers come from
Financial figures are the values Fortress Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.